Dollars for Profs
Dig Into University Researchers' Outside Income and Conflicts of Interest
Published Dec. 6, 2019
This database was last updated in December 2019 and should only be used as a historical snapshot. There may be new or amended records not reflected here.
Conflict of Interest
Institutions must file significant disclosures to the National Institutes of Health if they determine financial relationships could affect the design, conduct or reporting of the NIH-funded research. The NIH provided us with their entire financial conflict of interest database, with filings from 2012 through 2019.
Should you be removed from our database? Contact us at [email protected]. Read more below.
Martin Pollak
Beth Israel Deaconess Medical Center, Department: Na
Should you be removed from our database? Contact us at [email protected]. Read more below.
ApoLo1 Bio, LLC
Equity Interest - Non-publicly traded entity ( e.g., stock, stock option, or other ownership interest)
Because research identifying additional genetic modifiers at the APOL1 gene locus, finding epistatic modifiers of APOL1 penetrance, and identify biochemical modifiers of APOL1-mediated renal disease would be useful in advancing the interests of ApoLo1 Bio, LLC., and the investigator’s significant financial interest could directly and significantly affect the design, conduct, or reporting of the PHS-funded research, BIDMC has determined that the compensation constitutes a financial conflict of interest with the research for this grant under applicable PHS regulations (45 C.F.R. §50.601 et seq.).
APOL1 variants: Understanding the basis of disparities in rates of kidney disease
8. Project Narrative We have recently found that specific genetic variants in the APOL1 gene account for the very high rate of kidney disease in African Americans, and also confer resistance to Sleeping Sickness in Africa. We now want to understand the factors that combine with the high risk APOL1 genotype to cause overt kidney disease. Understanding how these differences in the APOL1 gene cause kidney disease in African Americans will have direct implications for improving all aspects of care for the growing number of people with this serious public health problem and for reducing the very large disparity in the rates of kidney disease.
Filed on April 14, 2015.
Tell us what you know about Martin Pollak's disclosure
We're still reporting about conflicts of interest. Is there something you'd like to tell us about this disclosure?
Martin Pollak filed other conflict of interest disclosures with the NIH:
| Name | Institution | Type | Company | Disclosed Value |
|---|---|---|---|---|
| Martin Pollak | Beth Israel Deaconess Medical Center | Conflict of Interest | APOL1 Bio, LLC | $150,000 - $199,999 |
| Martin Pollak | Beth Israel Deaconess Medical Center | Conflict of Interest | ApoLo1 Bio, LLC | Value cannot be readily determined |
Notes: When a more specific filing date is not available for an individual financial disclosure or conflict of interest form, we use the year the form was filed. If the year was not disclosed, we report the range of years covered by our public records requests. In a few cases, a start date was provided instead of a filing date. In those cases, we use the start date instead.
Fewer than 10% of records from the University of Florida and fewer than 1% of records from the University of Texas system were removed because they did not contain enough information.
ProPublica obtained additional financial disclosures and conflict of interest forms that we have not yet digitized and added to the database. You can download those disclosures in the ProPublica Data Store.